Table 2. Summary of outcomes Patient no.... | American Society of Hematology

Table 2.

Summary of outcomes

Patient no.	Donor	Age, y	Time to GVHD, d	Skin stage	Gl stage	Liver stage	Days to infliximab*	Response to infliximab	Death	Cause	Days to last follow-up†
1	1 Ag MM rel	37	28	3	0	0	41	CR	Yes	GVHD	83
2	1 Ag MM rel	62	41	1	1	0	53	CR	Yes	Relapse	165
3	HLA unrel	25	8	3	0	0	48	CR	No	—	682
4	HLA unrel	60	11	2	0	0	31	CR	No	—	298
5	HLA unrel	36	12	3	0	0	42	PR	Yes	GVHD	120
6	HLA unrel	45	16	0	1	0	7	PD	Yes	GVHD	178
7	HLA unrel	64	20	0	1	0	11	CR	No	—	640
8	HLA unrel	19	32	3	0	0	7	NR	Yes	Relapse	115
9	HLA unrel	62	36	0	3	0	37	CR	Yes	GVHD	19
10	HLA unrel	45	40	1	1	0	14	CR	No	—	806
11	HLA sib	55	18	1	0	0	45	NR	Yes	GVHD	50
12	HLA sib	62	19	0	2	0	18	NR	Yes	Pneumonia	231
13	HLA sib	63	20	0	1	0	5	CR	Yes	GVHD	257
14	HLA sib	40	23	0	0	1	41	CR	Yes	GVHD	144
15	HLA sib	47	30	0	3	1	4	PD	Yes	GVHD	99
16	HLA sib	27	31	0	4	0	6	CR	No	—	352
17	HLA sib	53	34	1	0	0	59	CR	No	—	390
18	HLA sib	53	40	0	1	0	7	CR	No	—	588
19	HLA sib	55	57	0	1	0	27	CR	Yes	GVHD	130
20	HLA sib	47	91	0	1	0	4	NR	No	—	861
21	HLA sib	29	122‡	0	0	1	47	NR	Yes	Relapse	161

Patient no.	Donor	Age, y	Time to GVHD, d	Skin stage	Gl stage	Liver stage	Days to infliximab*	Response to infliximab	Death	Cause	Days to last follow-up†
1	1 Ag MM rel	37	28	3	0	0	41	CR	Yes	GVHD	83
2	1 Ag MM rel	62	41	1	1	0	53	CR	Yes	Relapse	165
3	HLA unrel	25	8	3	0	0	48	CR	No	—	682
4	HLA unrel	60	11	2	0	0	31	CR	No	—	298
5	HLA unrel	36	12	3	0	0	42	PR	Yes	GVHD	120
6	HLA unrel	45	16	0	1	0	7	PD	Yes	GVHD	178
7	HLA unrel	64	20	0	1	0	11	CR	No	—	640
8	HLA unrel	19	32	3	0	0	7	NR	Yes	Relapse	115
9	HLA unrel	62	36	0	3	0	37	CR	Yes	GVHD	19
10	HLA unrel	45	40	1	1	0	14	CR	No	—	806
11	HLA sib	55	18	1	0	0	45	NR	Yes	GVHD	50
12	HLA sib	62	19	0	2	0	18	NR	Yes	Pneumonia	231
13	HLA sib	63	20	0	1	0	5	CR	Yes	GVHD	257
14	HLA sib	40	23	0	0	1	41	CR	Yes	GVHD	144
15	HLA sib	47	30	0	3	1	4	PD	Yes	GVHD	99
16	HLA sib	27	31	0	4	0	6	CR	No	—	352
17	HLA sib	53	34	1	0	0	59	CR	No	—	390
18	HLA sib	53	40	0	1	0	7	CR	No	—	588
19	HLA sib	55	57	0	1	0	27	CR	Yes	GVHD	130
20	HLA sib	47	91	0	1	0	4	NR	No	—	861
21	HLA sib	29	122‡	0	0	1	47	NR	Yes	Relapse	161

1 Ag MM rel indicates 1 antigen-mismatched, related; HLA sib, HLA-matched sibling; and HLA unrel, HLA-matched, unrelated.

Days from diagnosis of GVHD to infliximab.

Days from initiation of infliximab to last follow-up.

Patient received a donor lymphocyte infusion 20 days before clinical manifestations of acute GVHD.